<DOC>
	<DOCNO>NCT00593281</DOCNO>
	<brief_summary>Double-blind study compare pharmacokinetics , safety tolerability morphine administer subcutaneously ( SC ) without human recombinant hyaluronidase ( HYLENEX ) intravenously conduct patient hospice care set palliative care medicine set . In within-patient control study , eligible study patient receive single injection three method morphine administration , sequentially three consecutive day , accord order specify randomization schedule . Each three injection consist 5 mg morphine ( 1.0 mL 5 mg/mL solution ) . The HYLENEX injection 1 mL 150 unit . Although IV administration blind , two SC injection double-blinded , use volume normal saline ( 0.9 % sodium chloride ) placebo ( 1.0 mL ) HYLENEX .</brief_summary>
	<brief_title>INFUSE Morphine Study</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<criteria>1 . Males female least 18 year age patient San Diego Hospice &amp; Palliative Care recruit San Diego Hospice &amp; Palliative Care UCSD Center Pain Palliative Medicine . 2 . During treatment day study , opioid therapy morphine equivalent ≥ 60 mg oral morphine per day without unacceptable toxicity . 3 . Vital sign ( BP , HR , RR ) within normal range . 4 . Adequate venous access upper extremity . 5 . A negative pregnancy test ( female childbearing potential ) within 7 day prior first injection . 6 . Life expectancy ≥ ten day . 7 . Decisionmaking capacity . 8 . Signed , write IRBapproved informed consent . 1 . Known hypersensitivity history toxicity morphine . 2 . Morphine within 4 day prior first study medication injection anticipate receive morphine treatment day study . 3 . Any contraindication morphine . 4 . Known hypersensitivity naloxone . 5 . Known allergy hyaluronidase ingredient formulation HYLENEX . 6 . Known allergy bee vespid venom . 7 . Contraindication IV heparin lock know hypersensitivity heparin . 8 . Edema , infection , low extremity pelvic disorder might affect subcutaneous absorption thigh . 9 . Hemoglobin &lt; 10 g/dL . 10 . Presence medical condition would present unacceptable safety risk patient . 11 . Participation study investigational drug device within 30 day enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Hyaluronidase</keyword>
	<keyword>Hylenex</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>morphine</keyword>
	<keyword>absorption</keyword>
	<keyword>bioavailability</keyword>
	<keyword>PK study morphine patient pain</keyword>
</DOC>